在进展性慢性病和心房动中使用全身抗凝剂
Henning Hansen-Nootbaar1, Friedrich Stasche1, Oliver Ritter1
1Department of Internal Medicine I-Cardiology, Nephrology and Internal Intensive Medicine, Brandenburg University Hospital, Brandenburg Medical School (Theodor Fontane), Brandenburg an der Havel, Germany.
The Journal of international medical research
|April 25, 2025
概括
患有慢性病 (CKD) 和心房动 (AF) 的患者面临高出血风险. 系统性抗凝剂在这种CKD人群中没有减少血栓栓塞事件,建议谨慎使用,特别是在后期阶段.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 患有慢性病 (CKD) 的患者患上心房动 (AF) 的风险较高.
- 在CKD患者,特别是AF患者中,全身抗凝剂的最佳使用仍然不确定,特别是在晚期.
- 了解血栓栓塞和出血风险之间的平衡对于管理这些患者至关重要.
研究的目的:
- 为了确定患有CKD的患者中AF的患病率.
- 评估CKD患者有或没有AF的血栓栓塞和出血事件的发生率.
- 评估系统性抗凝药对CKD患者群体这些结果的影响.
主要方法:
- 追溯观察队列研究的设计.
- 包括146名患有不同病因的慢性病 (CKD) 的患者.
- 分析心房 (AF) 患病率,全身抗凝剂使用,以及跨CKD阶段的血栓栓塞和出血事件的发生率.
主要成果:
- 43.8%的CKD患者患有心房动 (AF),在CKD各个阶段的患病率相似.
- 血栓栓塞栓事件在AF患者中很少发生,但在晚期CKD中很常见.
- AF患者经历了更多的出血事件,特别是在CKD第四阶段.
结论:
- 系统性抗凝剂并没有减少AF的CKD患者的血栓栓塞事件.
- 在CKD患有AF的患者中,观察到增加的出血并发症,特别是在晚期.
- 建议在患有AF的CKD患者使用全身抗凝剂时谨慎使用,特别是在疾病晚期.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
585
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
585
01:22Heart Failure Drugs: Diuretics
312
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
312
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
01:11Renal Failure: Dose Adjustments
51
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
51
01:33Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K